October 2008
It works 100% of the time to eradicate cancer completely, and cancer does not recur even years later.
That is how researchers describe the most convincing cancer cure ever announced.
The weekly injection of just 100 billionths of a gram of a harmless glyco-protein (a naturally-produced molecule with a sugar component and a protein component) activates the human immune system and cures cancer for good, according to human studies among breast cancer and colon cancer patients, producing complete remissions lasting 4 and 7 years respectively. This glyco-protein cure is totally without side effect but currently goes unused by cancer doctors.
Normal Gc protein (also called Vitamin-D binding protein) , an abundant glyco-protein found in human blood serum, becomes the molecular switch to activate macrophages when it is converted to its active form, called Gc macrophage activating factor (Gc-MAF). Gc protein is normally activated by conversion to Gc-MAF with the help of the B and T cells (bone marrow-made and thymus gland-made white blood cells). But, as researchers explain it themselves, cancer cells secrete an enzyme known as alpha-N-acetylgalac tosaminidase (also called Nagalase) that completely blocks conversion of Gc protein to Gc-MAF, preventing tumor-cell killing by the macrophages. This is the way cancer cells escape detection and destruction, by disengaging the human immune system. This also leaves cancer patients prone to infections and many then succumb to pneumonia or other infections.
Although GcMAF is also called Vitamin-D binding protein, the activation of macrophages does not require Vitamin D.
GcMAF is a naturally made molecule and is not patentable, though its manufacturing process is patent protected. There is no evidence of any current effort to commercialize this therapy or put it into practice. Should such an effective treatment for cancer come into common practice, the income stream from health-insurance plans for every oncology office and cancer center in the world Would likely be reduced to the point of financial insolvency and hundreds of thousands of jobs would be eliminated.
Clipped from Artilce By Bill Sardi and Timothy Hubbell
[International Journal Cancer.2008 January15; 122(2):461-7]
Related articles:
[Cancer Immunology, Immunotherapy Volume 57, Number 7 / July 2008]
[Targeted Oncology 2007 April, 2 (2); 113-19]
[The Journal of Immunology, 1993 151 (5); 2794-2802]
[Neoplasia 2003 January; 5(1): 32–40]
[Cancer Research 1997 Jun 1; 57(11):2187- 92]
[Cancer Research 1996 Jun 15; 56(12):2827- 31]
[US Patent 5326749, July 1994; Cancer Research 1996 June 15; 56: 2827-31]
1 comment:
Apart of the results reported here, there are more resent works by Yamamoto.In July of this year a study on 16 prostate cancer patients was published in Translational Oncology.According to this study all 16 patients are cancer free after 7 years http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2510818
On the other hand, 16 HIV patiens who had received gcmaf treatment are cured after 7 years.The sudy will come out next January.An abstract can be seen in:
http://www.ncbi.nlm.nih.gov/pubmed/19031451?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_Discovery_RA&linkpos=3&log$=relatedarticles&logdbfrom=pubmed
I've been following Yamamoto's work since January 15,when it appeared in a immunology magazine,when I first read the study I devoted my constant attention to the news, I thought that it would be immeditely broadcast by radio and television and it would be the headlines of all the papers in the world.But not a word or a mention about it.A few months later the article by B.Sardi appeared in the web.After that new works by Yamamoto, mentioned above.Very,very few people know about this.
Results like these have never been reported.I don't know anything about Yamamoto but according to the studies published and to the time he has been involved in this reseach it seems to be respectable, reliable and trustworthy.
I'm not able to understand this silence
Post a Comment